PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW145768View Pathway |
drug action
Triclofos Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:36 Last Updated: October 07, 2023 at 16:36 |
PW145832View Pathway |
drug action
Triclosan Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:46 Last Updated: October 07, 2023 at 16:46 |
PW145824View Pathway |
drug action
Triethylenetetramine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:45 Last Updated: October 07, 2023 at 16:45 |
PW146558View Pathway |
drug action
Trifarotene Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:30 Last Updated: October 07, 2023 at 18:30 |
PW176155View Pathway |
Trifarotene Predicted Metabolism Pathway newHomo sapiens
Metabolites of Trifarotene are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 14:22 Last Updated: November 29, 2023 at 14:22 |
PW128161View Pathway |
drug action
Trifluoperazine Dopamine Antagonist Action PathwayHomo sapiens
Trifluoperazine is a trifluoro-methyl phenothiazine derivative. Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. It is indicated for the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
|
Creator: Omolola Created On: July 26, 2023 at 14:40 Last Updated: July 26, 2023 at 14:40 |
PW144937View Pathway |
drug action
Trifluoperazine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:44 Last Updated: October 07, 2023 at 14:44 |
PW128212View Pathway |
drug action
Triflupromazine - Dopamine Antagonist Action PathwayHomo sapiens
Triflupromazine is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Triflupromazine is used particularly to control violent behavior during acute episodes of psychotic disorders. It can also be used to control severe nausea and vomiting, severe hiccups, and moderate to severe pain in some hospitalized patients. Triflupromazine acts on the central nervous system. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT2B). Dopamine hypothesis states that dopamine abnormalities in the mesolimbic and prefrontal brain regions exist in schizophrenia.
|
Creator: Omolola Created On: August 03, 2023 at 11:37 Last Updated: August 03, 2023 at 11:37 |
PW144628View Pathway |
drug action
Triflupromazine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:04 Last Updated: October 07, 2023 at 14:04 |
PW128090View Pathway |
drug action
Triflupromazine Mechanism of Action Action PathwayHomo sapiens
Triflupromazine is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Triflupromazine is used particularly to control violent behavior during acute episodes of psychotic disorders. It can also be used to control severe nausea and vomiting, severe hiccups, and moderate to severe pain in some hospitalized patients. Triflupromazine acts on the central nervous system. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT2B). Dopamine hypothesis states that dopamine abnormalities in the mesolimbic and prefrontal brain regions exist in schizophrenia.
|
Creator: Omolola Created On: July 17, 2023 at 10:54 Last Updated: July 17, 2023 at 10:54 |